Home / Information / Lorlatinib
Lorlatinib
Lorlatinib is a 3rd generation TKI developed by Pfizer. The recommended dose is 100mg taken daily.
​
​
Documents
Name
Summary of Contents
Action
​Managing Lorlatinib Together
​
NEW
An overview and practical guide for patients by ALK-positive patients and medical experts.
Increased cardiovascular risk with Lorlatinib
​
NEW
Patients receiving lorlatinib have an increased risk of developing cardiovascular diseases, particularly heart failure and stroke.
Management of Side Effects​
A guide for health care professionals on the management of adverse effects arising from Lorlatinib.
Use of Lorlatinib with Paxlovid​​
Paxlovid is used to treat early Covid-19 infections. Here is Pfizer's statement about using it with Lorlatinib.
Crown Study 5-year Outcomes
This report contains information on the effectiveness of Lorlatinib for 1st line use.
Lorlatinib What to Expect (Pfizer)
A booklet from Pfizer on the side effects that patients may experience.
Weight Gain
Patients with weight gain of over 5% within 6 months developed significantly higher maximum gain
Lorlatinib - An Oncologist's Opinion
A discussion with Dr Camidge, a leading USA ALK+ expert.